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Abstract objective There is a high burden of both diabetes (DM) and tuberculosis (TB) in China, and this study
aimed to assess feasibility and results of screening patients with TB for DM within the routine healthcare
setting of six health facilities.
method Agreement on how to screen, monitor and record was reached in May 2011 at a stakeholders’
meeting, and training was carried out for staff in the six facilities in July 2011. Implementation started in
September 2011, and we report on 7 months of activities up to 31 March 2012.
results There were 8886 registered patients with TB. They were ﬁrst asked whether they had DM. If
the answer was no, they were screened with a random blood glucose (RBG) followed by fasting blood
glucose (FBG) in those with RBG ‡ 6.1 mm (one facility) or with an initial FBG (ﬁve facilities). Those
with FBG ‡ 7.0 mm were referred to DM clinics for diagnostic conﬁrmation with a second FBG.
Altogether, 1090 (12.4%) patients with DM were identiﬁed, of whom 863 (9.7%) had a known
diagnosis of DM. Of 8023 patients who needed screening for DM, 7947 (99%) were screened. This
resulted in a new diagnosis of DM in 227 patients (2.9% of screened patients), and of these, 226 were
enrolled to DM care. In addition, 575 (7.8%) persons had impaired fasting glucose (FBG 6.1 to
<7.0 mm). Prevalence of DM was signiﬁcantly higher in patients in health facilities serving urban
populations (14.0%) than rural populations (10.6%) and higher in hospital patients (13.5%) than those
attending TB clinics (8.5%).
conclusion This pilot project shows that it is feasible to screen patients with TB for DM in the routine
setting, resulting in a high yield of patients with known and newly diagnosed disease. Free blood tests for
glucose measurement and integration of TB and DM services may improve the diagnosis and man-
agement of dually affected patients.
keywords tuberculosis, diabetes mellitus, screening, China
Introduction
China is a country with 1.3 billion people (or 18.5% of the
world population) and has the second largest number of
tuberculosis (TB) cases (estimated at 0.9–1.2 million per
annum) in the world (WHO 2011a). China follows the
‘DOTS’ model for TB control and, over the last 20 years,
has had much success in reducing the burden of disease
caused by TB. Case detection rates are above 85%, and
treatment success rates in patients with new smear-positive
pulmonary tuberculosis (PTB) are above 90%. However,
TB is still a major public health problem, and rates of
multidrug resistant TB (MDR-TB = resistance to both
isoniazid and rifampicin) are high, with 6% of new cases
and 26% of retreatment cases estimated to have MDR-TB
(WHO 2011a).
Tropical Medicine and International Health doi:10.1111/j.1365-3156.2012.03068.x
volume 17 no 10 pp 1294–1301 october 2012
1294 ª 2012 Blackwell Publishing LtdAs a consequence of population growth, ageing, changed
lifestyle and urbanisation, the country has also witnessed
an escalating epidemic of diabetes mellitus (DM) (Danaei
et al. 2011; International Diabetes Federation 2011;
Alcorn & Ouyang 2012). Available data suggest that an
estimated 10% of people above the age of 15 years have
DM, with about half of those in rural areas and one-third
in urban areas being unaware of the problem. A recent
study in a nationally representative sample of over 46 000
adults conﬁrms these estimates, giving a ﬁgure of 92
million adults with DM and 148 million with pre-diabetes
(Yang et al. 2010).
A number of literature reviews, including systematic
reviews and meta-analyses, have shown that people with
DM have a signiﬁcantly increased risk of developing
active TB, which is 2–3 times higher than in those with
no DM (Stevenson et al. 2007; Jeon & Murray 2008;
Dooley & Chaisson 2009; Ruslami et al. 2010). DM
patients with TB also appear to experience worse treat-
ment outcomes than patients with no DM, with delays in
sputum culture conversion, an increased risk of death and
an increased risk of recurrent disease after successful
completion of treatment (Baker et al. 2011). Despite a
good national TB programme, it is likely that in a country
such as China, the diabetes epidemic is hampering TB
control efforts. Currently, routine screening and reporting
of patients with TB for DM in China does not take place
even though the links between the two diseases are
recognised.
In high HIV–TB burden countries, HIV testing and
counselling is the gateway to HIV prevention and care for
co-infected patients with TB, and the ways by which this
screening and reporting are performed have largely been
worked out (Harries et al. 2011). Given the current burden
of DM in China, patients with TB would merit being
screened for DM. A recently launched World Health
Organization (WHO)-Union Framework for Collaborative
activities to reduce the dual burden of DM and TB
recommends bidirectional screening of the two diseases
(WHO & IUATLD 2011). However, how this is best
performed and carried out in routine healthcare settings is
not known, and this knowledge gap needs to be addressed
(Jeon et al. 2010).
In China, a standardised procedure for screening
patients with TB for DM, a monitoring tool linked to the
TB registration system and quarterly system of reporting
were developed and agreed upon in the ﬁrst half of 2011
with implementation starting in the second half of the
year. This article describes the implementation, moni-
toring, results and challenges of screening patients with
TB for DM within routine healthcare settings in the
country.
Methods
This was a prospective observational implementation
project carried out in six TB clinics⁄hospitals within the
routine health services in China.
As a result of support from the World Diabetes Foun-
dation (WDF), a national stakeholders meeting was held in
Beijing, China, in May 2011, between the Union, WHO,
the World Diabetes Foundation (WDF) and national
diabetes, non-communicable disease and TB authorities to
review and discuss linkages between DM and TB, the need
for bidirectional screening and the WHO-Union Collabo-
rative Framework. Broad guidelines for how the screening
should be performed were worked out: ﬁve sites were
selected for screening patients with DM for TB (the subject
of a different paper), and 6 different sites were selected for
screening patients with TB for DM. These six sites were
Xinjiang Chest Hospital; Anding District CDC TB Clinic;
Number 1 and Number 2 TB Clinics of Guangzhou Chest
Hospital; Shandong Chest Hospital; and Shenyang Chest
Hospital (Figure 1). Details of the hospitals and TB clinics
are shown in Table 1. The TB clinic⁄hospitals were
selected because of their geographical locations (north-west
[Xinjiang Chest Hospital and Anding District CDC],
north-east [Shenyang Chest Hospital], south [Guangzhou
Chest Hospital], east [Shandong Chest Hospital]), high
prevalence of pulmonary TB in the surrounding commu-
nities and urban–rural mix.
In July 2011, a training workshop was held with
healthcare staff from the six sites to share standardised
guidelines for screening and referral of patients, and
monitoring and reporting the data. Registers and cohort
reporting forms were developed and printed and distrib-
uted to the study sites. Staff ofﬁcers returned to their
health facilities and provided in-service training for staff
working in the clinics. Implementation of activities started
in September 2011. It was agreed that data would be
reported in quarterly cohorts: Q3-2011 (September);
Q4-2011 (October to December); and Q1-2012 (January
to March).
Patients included all persons aged 15 years and older
who were consecutively diagnosed and registered with TB
from 1 September 2011 up to 31 March 2012.
Every patient with conﬁrmed TB started anti-TB treat-
ment immediately. Treatment regimens and anti-TB drug
formulations were in accordance with those recommended
by WHO (WHO 2009) and in line with National TB
Control Guidelines (Ministry of Health and Chinese Centre
on TB Control and Prevention 2008). The screening for
DM followed national guidelines that stipulate that a
fasting blood glucose (FBG) is carried out using venous
plasma and biochemical analyser with cut-off thresholds in
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In brief, FBG ‡7.0 mm (126 mg⁄dl) indicates DM; FBG of
between 6.1 and <7.0 mm (110 to <126 mg⁄dl) indicates
impaired fasting glucose; FBG < 6.1 mm (110 mg⁄dl) is
normal. Sites determined whether to (i) ﬁrst screen patients
with a random blood glucose (RBG) followed by FBG at
Table 1 Details of the six hospitals involved in the pilot study in China
Xinjiang
Chest
Hospital
Anding
District CDC
TB Clinic
Number 1 Clinic
of Guangzhou
Hospital
Number 2 Clinic
of Guangzhou
Hospital
Shandong
Chest
Hospital
Shenyang
Chest
Hospital
Number of
Hospital Beds
300 0 0 0 680 800
Number of daily
outpatient visits
170 20 200 100 200 450
Number of daily
TB patient visits
110 20 200 100 100 40
Number of TB
doctors
139 2 16 9 30 72
Number of TB
Nurses
167 0 31 20 72 144
Main source of
patients
Rural Rural Urban and migrant
population
Urban and migrant
population
Urban and
rural
Urban
Sites to where DM
suspects are
referred
DM⁄TB clinic
at the same
hospital
Dingxi Number
2 Hospital
Hospital
authorised by
medical insurance
contract
Hospital
authorised by
medical insurance
contract
Jinan Central
Hospital
DM⁄TB clinic
at the same
hospital
Distance of DM
clinic from TB
clinic (Km)
Not applicable 1.0 Variable Variable 0.5 Not applicable
TB, tuberculosis; DM, diabetes mellitus.
Xinjiang
Shenyang
Anding
Six TB clinics in China
Shandong
Guangzhou
Figure 1 Map of China indicating where
the six facilities are situated.
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screen patients just with FBG. If patients with TB were
found to have FBG ‡7.0 mm, the patients were referred to
diabetes services for a deﬁnitive diagnosis of DM by
measuring a second FBG, and if this was ‡7.0 mm, the
diagnosis was conﬁrmed (although it was understood that
this diagnosis may include stress-induced temporary hy-
perglycaemia). Tests for blood glucose had to be paid for
by the patient (about USD$1.6–1.8 per test). Whether DM
was conﬁrmed or excluded at the diabetes clinic, the
patients were referred back to the TB clinic for continued
anti-TB treatment.
Tuberculosis patients with newly diagnosed DM were to
be enrolled into DM care. Patients with TB with known
DM were already in diabetes care, but if their blood
glucose levels were high at the time of TB registration, they
were referred back for better management.
A parallel register (Figure 2) was developed for record-
ing data about whether the patient was already known to
have DM and was under DM care. If the patient had no
known history of DM, screening was carried out with
RBG⁄FBG as described earlier. Patients with newly diag-
nosed DM were to be enrolled to diabetes services, and this
information was captured in the parallel register. The DM
register was linked to the patient TB register through the
TB registration number, which was recorded in both sets of
documents.
Standardised quarterly report forms were developed and
used for the recording of screening data. These were
compiled by TB clinic staff 30 days after the end of the
quarter to allow for the collection of data from diabetes
clinics. Reports were kept at the facilities and also sent to
the Union China Ofﬁce and TB clinical centre of the China
Centre for Disease Control (CDC) for collation. Supervi-
sion and site visits were carried out by staff of the Union
China Ofﬁce and the TB clinical centre of the China CDC
early on during the period of the study.
Individual patient data were received and cross-checked
by staff of the Union China Ofﬁce and the TB clinical
centre of the China CDC, then double entered to an
EXCEL ﬁle and analysed. Comparisons between groups
were made using the chi-squared test, and odds ratios (OR)
were calculated where appropriate with 95% conﬁdence
intervals (CI). The level of signiﬁcance was set at 5%.
National authorities in China stipulated that this was a
pilot project aiming to test the feasibility of the DM
screening approach amongst patients with TB with a view
to learning lessons for national scale up. As such, formal
ethics approval in China was deemed not to be necessary.
However, permission to use, report and publish the
collected data was obtained from the Union Ethics Advi-
sory Group, Paris, France.
Results
In Number 2 TB Clinic of Guangzhou Chest Hospital,
screening was carried out ﬁrst with RBG followed by FBG
for those with a blood glucose ‡6.1 mm (110 mg⁄dl).
Results for the three quarterly periods combined are shown
in Table 2. All 541 patients were screened according to
guidelines: 3.3% of patients had a known diagnosis of
DM and were receiving DM care, and 3.2% of those tested
had a new diagnosis of DM. All patients with newly
diagnosed DM were enrolled to DM care. Five patients
Quarter
and Year
TB
Reg.
Number
Name Known
DM
Y/N
Screen
with
RBG
Date
Result
of
RBG
Screen
with
FBG
Date
Result
of
FBG
New
DM
Y/N
Known
or New
DM
Y/N
New or Known
DM referred
to DM care
Date
New DM
enrolled
to DM care
Date
Figure 2 Register of Diabetes (DM) screening in patients with TB. Ten rows per page (therefore ten patients per page). DM, diabetes
mellitus; TB, tuberculosis; RBG, Random Blood Glucose; FBG, Fasting Blood Glucose. If answer to ‘Known DM’ is No, then screen for
DM. If RBG ‡ 6.1 mm (110 mg⁄dl), do second screen with FBG at next visit. If FBG ‡ 7.0 mm (126 mg⁄dl), then refer to DM services for
the conﬁrmation of diagnosis of DM. Refer all new patients with Diabetes and known patients with Diabetes to Diabetes care.
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and <7.0 mm.
In the other ﬁve clinics⁄hospitals, screening was carried
out with an initial FBG. Results for the facilities and for
the three quarterly periods combined are shown in Table 3.
Of 8345 patients, 10.1% had a known diagnosis of DM
and were receiving DM care. Of the remaining 7500
patients, 7361 (98%) were screened with FBG. One
hundred thirty-nine patients refused to be screened for
reasons not formally ascertained. Of those screened, 282
were found to have FBG ‡7.0 mm of whom 210 (2.9% of
those screened) were conﬁrmed to have DM on subsequent
testing at the diabetes clinic. All patients with newly
diagnosed DM except one were enrolled in DM care. Five
hundred seventy patients had impaired FBG with blood
glucose levels between 6.1 and <7.0 mm.
In the three facilities serving a predominately urban
population (Shenyang and the two clinics of Guangzhou),
the prevalence of DM (new and known) was 13.8%, which
was signiﬁcantly higher than in the two facilities serving
a predominantly rural population (Anding and Xinjiang)
where the prevalence of DM (new and known) was 10.6%
[OR 1.35, 95% CI 1.16–1.57, P < 0.001]. In the one
facility with a mixed urban–rural population (Shandong),
the prevalence of DM (new and known) was 8.8%. In the
three hospitals, the prevalence of DM (new and known)
was 12.9%, which was signiﬁcantly higher than the DM
prevalence of 8.5% found in the three TB clinics (OR 1.61,
95% CI 1.30–2.00, P < 0.001).
Results for DM screening and diagnosis in patients with
TB for quarter 3-2011, quarter 4-2011 and quarter 1-2012
for all six facilities combined are shown in Table 4. In
total, there were 8886 patients consecutively registered for
TB, of whom 1090 (12.4%) were diagnosed with DM (863
with known DM and 227 with new DM). Although no
action was taken on patients with FBG between 6.1 and
<7.0 mm, 575 (7.8%) of 7884 patients with TB screened
had FBG results in this range, indicating they had impaired
fasting blood glucose. For each of the quarters, between
9% and 10% of patients were found to have a known
diagnosis of DM, over 98% of patients not known to have
DM were screened, and of those screened between 2.5%
and 3.5% were found to have newly diagnosed DM.
Although some of these proportions between the quarters
were statistically different, these were not of clinical or
public health signiﬁcance.
Discussion
This is the ﬁrst study reported from China about routine
implementation of screening patients with TB for DM. The
overall prevalence of DM in patients with TB was 12.4%.
Health facilities serving urban populations and hospitals
had a higher prevalence of DM compared with health
facilities serving rural populations and clinics, respectively.
The majority of patients were already known to have DM,
probably a high proportion compared with many other
high TB burden countries. However, nearly 3% of those
screened were found to have new DM, and if it had not
been for the screening process, these patients would not
have been identiﬁed. If DM screening was scaled up
nationwide and implemented at the high levels of perfor-
mance achieved in this pilot project, a prevalence of 3% of
1 million patients with TB translates to 30 000 new DM
cases diagnosed each year, which is an important contri-
bution to case ﬁnding of DM.
If this pilot project was scaled up countrywide, another
78 000 (7.8%) new cases could be identiﬁed as having
impaired fasting glucose, an indicator for future high risk
of DM and also future morbidity such as stroke (Lee et al.
2012; Perreault et al. 2012). While some of this may be
attributed to stress hyperglycaemia because of TB comor-
bidity, it is nonetheless an indicator of future risk. Lifestyle
counselling, health promotion and follow-up may prevent
or delay the onset of DM in a substantial number of these
cases (Perreault et al. 2012). Given that patients with TB
anyway are counselled on healthy diet, avoidance of
Table 2 Screening patients with TB for DM at Number 2 Clinic in
Guangzhou Chest Hospital: data combined for the three quarters
Registered patients with TB screened for
and diagnosed with DM Number
Number of patients with TB registered
over the three quarters
541
Number (%) with known diagnosis of DM 18 (3.3%)
Number needing to be screened with RBG 523
Number (%) screened with RBG 523 (100%)
Number with RBG ‡ 6.1 mm and needing
to be screened with FBG
54
Number screened with FBG 54 (100%)
FBG results
FBG < 6.1 mm 32
FBG 6.1 to 7.0 mm 5
FBG ‡ 7.0 mm 17
Number with FBG ‡ 7.0 mm referred
to DM services
17
Number (%) newly diagnosed with DM* 17 (3.2%)
Number (%) patients with newly diagnosed
DM enrolled to DM care
17 (100%)
Number (%) with known or newly
diagnosed DM
35 (6.5%)
TB, tuberculosis; DM, diabetes mellitus; RBG, random blood
glucose; FBG, fasting blood glucose.
*Percentage of screened patients with TB with a new diagnosis of
DM.
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physical activity, linking this advice at no or marginal
additional costs would be beneﬁcial in an overall public
health strategy to prevent DM.
While the prevalence rate of 12.4% DM amongst
patients with TB found in this study is 28% higher than the
9.7% prevalence of DM reported in the large China
national survey (Yang et al. 2010), the latter was based on
a 2-h 75-g oral glucose tolerance test rather than FBG. In
the national survey by Yang et al., 47% of patients with a
diagnosis of DM had normal FBG, and by extrapolation,
this suggests that the TB cohorts would have had about
twice the prevalence of DM as the general adult population
if they had been screened with an oral glucose tolerance
test. Similarly, the 7.8% rate of impaired fasting glucose in
patients with TB is more than 3 times higher than in the
national study. Any serious comparisons would require
further adjustments for age, body mass index and socio-
economic status that inﬂuence DM prevalence – all likely
to be lower for the TB cohort than the general population.
Such comparative analysis needs further data extraction
and research and was not the purpose of this study.
All new patients were enrolled to DM care. Although
data were not formally captured in this study, round table
discussions with healthcare staff indicated that those with
known DM were already in care and those with elevated
blood glucose levels were referred back earlier to their
diabetes services for improved treatment and management.
Table 4 Screening of patients with TB for DM in quarter 3-2011, quarter 4-2011, and quarter 1-2012: data combined for the 6 facilities
Registered patients with TB screened and
diagnosed with DM Q3-2011 Q4-2011 Q1-2012 Total
Number of patients with TB registered in the quarter 1406 3676 3804 8886
Number with known diagnosis of DM 132 (9.4%) 344 (9.4%) 387 (10.2%) 863 (9.7%)
Number who should have been screened for DM
(either RBG or FBG)
1274 3332 3417 8023
Number who were screened for DM (either RBG or FBG) 1270 (99.7%) 3311 (99.4%) 3366 (98.6%) 7947 (99.1%)
Number newly diagnosed with DM* 33 (2.6%) 78 (2.4%) 116 (3.4%) 227 (2.9%)
Number with known or newly diagnosed DM 165 (11.4%) 422 (11.5%) 503 (13.4%) 1090 (12.4%)
TB, tuberculosis; DM, diabetes mellitus; RBG, random blood glucose; FBG, fasting blood glucose
*Percentage of screened patients with TB with a new diagnosis of DM.
Table 3 Screening patients with TB for DM at the ﬁve other health facilities in China: data combined for the three quarters
Registered patients with TB
screened and diagnosed with DM
Anding
TB Clinic
No. 1. Clinic
Guangzhou
Shandong
Hospital
Shenyang
Hospital
Xinjiang
Hospital Total
Number of patients with TB
registered over the three quarters
185 545 1060 4240 2315 8345
Number (%) with known
diagnosis of DM
6 (3.2%) 46 (8.4%) 64 (6.0%) 533 (12.6%) 196 (8.5%) 845 (10.1%)
Number needing to be screened
with FBG
179 499 996 3707 2119 7500
Number screened with FBG 168 (93.9%) 493 (98.8%) 995 (99.9%) 3586 (96.7%) 2119 (100%) 7361 (98.1%)
FBG results
FBG < 6.1 mm 149 438 896 3082 1944 6509
FBG 6.1 to 7.0 mm 15 37 67 336 115 570
FBG ‡ 7.0 mm 4 18 32 168 60 282
Number with FBG ‡ 7.0 mm
referred to DM services
4 18 32 168 60 282
Number (%) newly diagnosed
with DM*
2 (1.2%) 18 (3.7%) 29 (2.9%) 101 (2.8%) 60 (2.8%) 210 (2.9%)
Number (%) patients with newly
diagnosed DM enrolled to
DM care
2 (100%) 17 (94%) 29 (100%) 101 (100%) 60 (100%) 209 (99.5%)
Number (%) with known or
newly diagnosed DM
8 (4.3%) 64 (11.9%) 93 (8.8%) 634 (15.4%) 256 (11.1%) 1055 (13.0%)
TB, tuberculosis; DM, diabetes mellitus; RBG, random blood glucose; FBG, fasting blood glucose.
*Percentage of screened patients with TB with a new diagnosis of DM.
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mean 124 000 patients with DM (known and new) being
referred for care and treatment of their endocrine disease,
which would not only beneﬁt their diabetes but might
improve TB treatment outcomes.
Screening procedures, either by RBG followed by FBG or
initially by FBG alone, were equally acceptable in each of
the sites, and the few patients who did not undergo blood
tests either felt they were well enough not to need further
blood tests or were concerned about costs of laboratory
investigations. There appeared to be no particular prob-
lems with TB healthcare staff collecting data on blood
glucose results, and some initial problems with under-
standing how the quarterly forms should be completed
were solved through site supervision that took place just
before the end of the ﬁrst quarter.
One of the important problems with the screening
process, which is undertaken soon after TB registration and
at the start of anti-TB treatment, is that TB may induce
infection-related hyperglycaemia. In four studies assessing
blood glucose levels at multiple points during the course of
anti-TB treatment (Kishore et al. 1973; Goyal et al. 1978;
Singh et al. 1984; Oluboyo & Erasmus 1990), the preva-
lence of hyperglycaemia decreased over time, leading to the
suggestion that screening should occur later on or after TB
treatment has been completed or false-positive DM diag-
noses might occur. This may be the explanation of why
some patients initially found to have FBG ‡ 7.0 mm were
not conﬁrmed as having DM with subsequent tests.
However, we feel it is better to err on the side of over-
diagnosis of DM and screen, diagnose and refer earlier on in
the course of TB treatment because this allows opportuni-
ties to intervene and better control DM and inﬂuence TB
treatment outcomes. We are unsure of the implications or
the best management approach for the signiﬁcant number
of patients with TB (nearly 8%) with impaired FBG, and
this is an area needing further research. Providing lifestyle
counselling as indicated above is one such credible option.
Although referral of TB cases for the conﬁrmation of
diagnosis and enrolment into DM care was managed
well in this pilot project, this is an area in need of
improvement. In the context of HIV-associated TB,
different geographical locations of HIV and TB clinics pose
problems for the timely referral of cases for appropriate
care and management (Lawn & Wood 2012), while
integration of services appears to be the most efﬁcient
model both from the health services’ and patients’ point of
view (Howard & El-Sadr 2010). Given the scale of the two
diseases in China, colocation and integration of services
should be considered with TB healthcare staff cross-trained
in DM care and management so that dually affected
patients can be cared for within the same clinic until their
TB disease is cured. This approach would also best ﬁt
China’s current strategy of decentralisation where at the
primary healthcare level, the two diseases would be
managed within the same clinic.
The strengths of this study are that we implemented
screening within the routine system, and no special budget
was set aside for the implementation of this activity. The
six sites have already decided to continue with the current
approach, and other sites are being considered for the
expansion of this screening activity. In our opinion, this
approach provides substantial public health beneﬁts, not
least of which is the start of cooperation and collaboration
between communicable disease and non-communicable
disease programmes. The cost of the blood test for glucose
measurement, although only between USD $1.6 and 1.8, is
still an issue, and we would like to advocate that for
patients with TB, who often come from poor communities,
these costs are met by the health services rather than out of
pocket for the patient.
Limitations include some of the problems discussed
above, such as the difﬁculties in knowing whether a high
FBG in the context of TB means true DM disease or
infection-induced hyperglycaemia. Further research in this
area, possibly with tests such as glycosylated haemoglobin
(HbA1C) or oral glucose tolerance tests, is needed. Mea-
surementofHbA1Cprovidesanindexofbloodglucoselevels
over a period of 2–3 months and is not subject to the rapid
swingsthatcanoccurwithrandomandfastingbloodglucose
measurements (International Expert Committee 2009; Ku-
mar et al. 2010; WHO 2011b).Further prospective research
isalsoneededtoassesstheeffectofbetterDMcontrolonTB
treatment outcomes and whether this leads to a decrease in
the reported risk of recurrent TB (Baker et al. 2011).
Conclusion
With the launch of the WHO and Union Collaborative
Framework for the care and control of Diabetes and
Tuberculosis, it is important that countries with a high dual
burden of the two diseases work out how best to screen for
each disease and manage detected cases within the routine
health services. Screening for DM in TB clinics should lead
to better and earlier detection of DM, earlier and better
treatment of DM (which might have gone unrecognised)
and improved clinical outcomes on anti-TB treatment. This
pilot project shows the way and should be of beneﬁt not
only for China but also for the global community.
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